Diagnostic And Prognostic Value of Glypican 3 as A Biomarker in Diagnosis of Hepatocellular carcinoma In Egyptian Patients with Hepatitis C Virus Related Cirrhosis Before And After Interventional Treatment

Abstract

Hepatocellular carcinoma (HCC) is the third deadliest and fifth most common cancer worldwide, despite the widespread use of surveillance programs in at risk populations, more than half of HCC cases are diagnosed late, and curative therapies such as surgical resection, radiofrequency ablation (RFA) or TACE are possible in less than 30% of patients. In Egypt, HCC is the first most common cancer in men and the second most common cancer in women according to GLOBOCAN 2012 (WHO project for Globalal Cancer statics estimation) Although AFP is a useful serological marker for HCC diagnosis, the false negative rate or false positive rate with AFP level alone may be as high as 40 %, especially for its early diagnosis or the finding of small size HCC, also AFP is elevated in pregnancy and other types of cancer such as germ cell, stomach, biliary tract and pancreatic tumors